Teijin and Hilleman Laboratories Partner to Advance Cell and Gene Therapy CDMO
Friday, November 01, 2024
Teijin Limited and Hilleman Laboratories have announced a strategic partnership to expand their contract development and manufacturing organization (CDMO) business in the field of cell and gene therapy.
The partnership aims to leverage the strengths of both companies to develop and manufacture cell and gene therapy products. By combining their expertise, they seek to strengthen support for Japanese customers expanding into the Asia-Pacific region and attract overseas customers to the Japanese market.
A key aspect of the partnership involves the establishment of a cell processing center in Singapore. Teijin's extensive knowledge and experience in regenerative medicine will be shared with Hilleman Laboratories to support this initiative.
Both companies are committed to driving innovation in the field of regenerative medicine and providing advanced solutions to meet the evolving needs of the global healthcare market.
The demand for CDMO services in cell and gene therapy is on the rise, driven by increasing technical complexity and specialization. Teijin's comprehensive CDMO platform, coupled with Hilleman Laboratories' expertise, positions the partnership to capitalize on this growing market.
By combining their resources and capabilities, Teijin and Hilleman Laboratories aim to become a leading player in the cell and gene therapy CDMO industry, delivering innovative solutions to patients worldwide.
Source: teijin.com
